Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$27.99
▲ $0.10 (+0.4%)
Market data updated: 09/19 12:24 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$27.70 - $29.01
52-Week Range
$13.74 - $65.30
Beta
—
Next Earnings
02.11.2026
Support
$24.24
Resistance
$37.70
HIMS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-50.2% (1Y)
Strengths: 9/25 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 59.0%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 5.9% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
53
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
58
Value
45
Momentum
46
Risk
48
Sentiment
50
Fundamental
66
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Hims & Hers Health, Inc.** has focused on its strong **second-quarter 2026 revenue growth**, which surged **38.2%**, prompting the company to raise its full-year outlook despite reporting an **$86.3 million net loss**. Analysts highlight momentum in **weight-loss services, international expansion, and AI-driven healthcare**, though concerns persist over **declining profit margins and regulatory uncertainty**, particularly around FDA oversight. Investor attention remains divided between growth potential and cost pressures.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Hims & Hers Health, Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 6 vs. 6 out of the last 20 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
4
🎯 Conviction (vs. Emotion)
41
Psychology
55
Fundamentals
66
Technical
46
Valuation
45
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-21%
Market Narrative
42
Fundamental Reality
41
Narrative Gap
+1
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior here is *conflicted*—high sentiment (98/100) clashes with weak momentum and neutral RSI, creating a narrative-reality gap (11 points). The dominant absence of a single state suggests indecision: euphoria and panic selling both score high but lack clear execution (low volume, low volatility). The key question is whether the positive sentiment will sustain or if traders will exit cautiously, given the price’s underperformance relative to peers and fundamentals. The lack of herding or anchoring implies no clear consensus, leaving room for volatility if catalysts emerge.
Updated: 09/09/2026, 05:08 AM
What could change this?
👥 What the crowd believes
"Q2 sales jumped 38.2% [...] HIMS raised its 2026 revenue outlook"
"HIMS has entered the second half of 2026 with weight-loss, international and AI momentum"
"margin contraction [...] and FDA uncertainty remain"
"Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention [...] Reasons to Retain Hims & Hers Stock in Your Portfolio"
📈 13D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 96/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for HIMS reflects deep methodological disagreements about valuation, risk, and market psychology. Samuel Armstrong Nelson’s high score suggests the stock may be oversold and ripe for a cyclical rebound, aligning with his technical and momentum-driven approach. In contrast, Benjamin Graham’s near-zero score and Jesse Livermore’s negative verdict highlight a fundamental and trend-based rejection: the stock fails Graham’s defensive metrics and runs counter to Livermore’s core rule of trading with the prevailing trend. Meanwhile, the mixed-to-negative scores from Howard Marks, Peter Lynch, and Gerald Loeb indicate concerns over overvaluation or excessive risk, while Morgan Housel’s zero score underscores volatility that could deter patient, long-term investors. Fisher and Smith’s moderate scores imply the stock has merit but lacks the exceptional quality or long-term conviction they demand, while Mackay and Marks (Market Cycle) see it as relatively unexciting or early-stage, far from manic or overextended.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 96
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 83
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 70
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 70
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 66
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 61
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 48
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 38
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 38
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 38
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 36
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 15
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 5 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
73.8%
Operating Margin
4.5%
Net Margin
5.5%
EBITDA Margin
6.8%
ROE
23.7%
ROA
6.0%
ROIC
—
EPS
$0.57
Cash
$228.62M
Total Debt
—
Current Ratio
1.90
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$2.09
Tangible Book Value per Share (Tangible NAV)
$0.26
Sentiment based on basic keywords (not AI) — 6 positive, 8 neutral, 6 negative out of the last 20 articles.
SeekingAlpha · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Schaeffer's Investment Research · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 13.9.2026
Motley Fool · 13.9.2026
SeekingAlpha · 12.9.2026
Yahoo · 11.9.2026
GuruFocus.com · 11.9.2026
Yahoo · 11.9.2026
Investing.com · 11.9.2026
Bankless · 10.9.2026
Yahoo · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Yahoo · 8.9.2026
Zacks · 8.9.2026
Hims & Hers Health, Inc. (HIMS) currently has a StockIQ AI score of 53/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
HIMS currently scores 53/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
HIMS's technical score is 46/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 59.0%; Operating margin is stable or improving over time; Return on equity (ROE): 23.7% — strong.
Based on the real signals StockIQ computed: ATR: 5.9% of price; Earnings per share (EPS) growth: -3.8%; Price is below the 50-day average.
StockIQ has no recorded dividend payment history for HIMS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Boughton Soleil | Open Market Sale | 2.9.2026 | 3,458 | -3,458 | $28.33 |
| Dudum Andrew | Other Transaction | 27.8.2026 | 103,406 | -977,566 | — |
| Dudum Andrew | Other Transaction | 27.8.2026 | 977,566 | -977,566 | — |
| Dudum Andrew | Gift | 25.8.2026 | 0 | -463,289 | — |
| Dudum Andrew | Gift | 25.8.2026 | 463,289 | -463,289 | — |
| Okupe Oluyemi | Exercise of Derivative Securities | 19.8.2026 | 4,938 | +4,938 | $5.01 |
| Okupe Oluyemi | Exercise of Derivative Securities | 19.8.2026 | 4,938 | -4,938 | — |
| Okupe Oluyemi | Open Market Sale | 19.8.2026 | 4,938 | -4,938 | $29.99 |
| Boughton Soleil | Open Market Sale | 19.8.2026 | 25,111 | -25,111 | $27.55 |
| Autor Deborah M. | Open Market Sale | 18.8.2026 | 16,773 | -16,773 | $27.85 |
| Okupe Oluyemi | Exercise of Derivative Securities | 17.8.2026 | 9,388 | -9,388 | — |
| Okupe Oluyemi | Open Market Sale | 17.8.2026 | 9,388 | -9,388 | $27.89 |
| Okupe Oluyemi | Exercise of Derivative Securities | 17.8.2026 | 9,388 | +9,388 | $5.01 |
| Becklund Irene | Exercise of Derivative Securities | 14.8.2026 | 1,394 | -1,394 | — |
| Becklund Irene | Exercise of Derivative Securities | 14.8.2026 | 3,880 | -3,880 | — |
| Becklund Irene | Exercise of Derivative Securities | 14.8.2026 | 4,345 | -4,345 | — |
| Payne Christopher D | Exercise of Derivative Securities | 14.8.2026 | 545 | -545 | — |
| Payne Christopher D | Exercise of Derivative Securities | 14.8.2026 | 545 | +545 | — |
| Becklund Irene | Exercise of Derivative Securities | 14.8.2026 | 4,066 | -4,066 | — |
| Becklund Irene | Tax Withholding in Shares | 14.8.2026 | 6,490 | -6,490 | $28.15 |
| Becklund Irene | Exercise of Derivative Securities | 14.8.2026 | 13,685 | +13,685 | — |
| Elshenawy Mohamed | Exercise of Derivative Securities | 14.8.2026 | 23,514 | -23,514 | — |
| Elshenawy Mohamed | Exercise of Derivative Securities | 14.8.2026 | 100,000 | -100,000 | — |
| Elshenawy Mohamed | Exercise of Derivative Securities | 14.8.2026 | 188,285 | +188,285 | — |
| Elshenawy Mohamed | Exercise of Derivative Securities | 14.8.2026 | 64,771 | -64,771 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
54,945,417 shares short as of 2026-08-31 · vs. 62,215,733 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
64.2% of trading volume this week was short selling, vs. 65.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology